Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 7/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16598882 | 0.93 | GPR183 (0.71) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL17954415 | 0.93 | GPR183 (0.71) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL16599065 | 0.90 | GPR183 (0.68) | GPR183KMT2AMEN1HRH4KDM4E | |
| SCHEMBL17856076 | 0.90 | GPR183 (1.00) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL17938686 | 0.88 | GPR183 (0.80) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL17954139 | 0.88 | GPR183 (0.64) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL16598766 | 0.87 | KMT2A (0.73) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL16598709 | 0.85 | KMT2A (0.62) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL16598576 | 0.85 | GPR183 (0.70) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL16598763 | 0.85 | GPR183 (0.61) | GPR183KMT2AMEN1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
| WO-2015048570-A2 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214951-A1 | EBI2 MODULATORS | BIRC2, HAVCR2, MAVS | GPR183 22/4885KMT2A 1057/4885MEN1 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.